Måndag 23 Juni | 23:15:36 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2025-11-27 08:00 Kvartalsrapport 2025-Q3
2025-08-28 08:00 Kvartalsrapport 2025-Q2
2025-06-25 N/A X-dag ordinarie utdelning PRLD 0.00 SEK
2025-06-24 N/A Årsstämma
2025-05-30 - Kvartalsrapport 2025-Q1
2025-02-28 - Bokslutskommuniké 2024
2024-11-27 - Kvartalsrapport 2024-Q3
2024-08-28 - Kvartalsrapport 2024-Q2
2024-05-27 - Årsstämma
2024-05-17 - Kvartalsrapport 2024-Q1
2024-05-15 - X-dag ordinarie utdelning PRLD 0.00 SEK
2024-02-21 - Bokslutskommuniké 2023
2023-11-27 - Extra Bolagsstämma 2023
2023-11-27 - Kvartalsrapport 2023-Q3
2023-08-29 - Kvartalsrapport 2023-Q2
2023-05-12 - X-dag ordinarie utdelning PRLD 0.00 SEK
2023-05-11 - Årsstämma
2023-05-11 - Kvartalsrapport 2023-Q1
2023-02-21 - Bokslutskommuniké 2022
2022-11-30 - Kvartalsrapport 2022-Q3
2022-08-29 - Kvartalsrapport 2022-Q2
2022-08-04 - Extra Bolagsstämma 2022
2022-05-23 - X-dag ordinarie utdelning PRLD 0.00 SEK
2022-05-20 - Årsstämma
2022-05-20 - Kvartalsrapport 2022-Q1
2022-02-22 - Bokslutskommuniké 2021
2021-11-23 - Kvartalsrapport 2021-Q3
2021-08-31 - Kvartalsrapport 2021-Q2
2021-05-06 - X-dag ordinarie utdelning PRLD 0.00 SEK
2021-05-05 - Årsstämma
2021-05-05 - Kvartalsrapport 2021-Q1
2021-02-24 - Bokslutskommuniké 2020
2020-11-17 - Kvartalsrapport 2020-Q3
2020-08-28 - Kvartalsrapport 2020-Q2
2020-05-21 - X-dag ordinarie utdelning PRLD 0.00 SEK
2020-05-20 - Årsstämma
2020-05-14 - Kvartalsrapport 2020-Q1
2020-02-13 - Bokslutskommuniké 2019
2019-11-20 - Kvartalsrapport 2019-Q3
2019-08-28 - Kvartalsrapport 2019-Q2
2019-05-16 - Årsstämma
2019-05-16 - Kvartalsrapport 2019-Q1
2019-05-10 - X-dag ordinarie utdelning PRLD 0.00 SEK
2018-11-20 - Kvartalsrapport 2018-Q3
2018-08-28 - Kvartalsrapport 2018-Q2
2018-05-17 - X-dag ordinarie utdelning PRLD 0.00 SEK
2018-05-16 - Årsstämma
2018-05-16 - Kvartalsrapport 2018-Q1
2018-02-14 - Bokslutskommuniké 2017
2017-11-23 - Kvartalsrapport 2017-Q3
2017-08-25 - Kvartalsrapport 2017-Q2
2017-05-22 - X-dag ordinarie utdelning PRLD 0.00 SEK
2017-05-19 - Årsstämma
2017-05-19 - Kvartalsrapport 2017-Q1

Beskrivning

LandSverige
ListaNordic SME Sweden
SektorHälsovård
IndustriMedicinteknik
Prolight Diagnostics utvecklar testsystem inom POCT (Point of care testning). Testerna används utanför sjukhuslaboratorium för att möjliggöra snabba bedömningar av patienters hälsa. Bolagets POCT-Plattform är i utveckling med avsikt att mäta flera biomarkörer samtidigt. En viktig del i arbetet är således att korta ner tiden för provresultaten, särskilt viktigt för patienter med hjärtbesvär. Bolaget grundades år 1999 och har sitt huvudkontor i Lund.
2025-06-23 19:00:00

Prolight Diagnostics (“Prolight” or the “Company”) is pleased to announce that additional subscription commitments have been received from the Company's board of directors and management in the ongoing rights issue of shares that Prolight resolved on, following approval from the subsequent extraordinary general meeting, on May 21, 2025 (the “Rights Issue”). The Company's nominated Chairman of the Board, Fredrik Alpsten, has undertaken to subscribe for shares of SEK 3 million, the Company's Board member Kiarash Farr has committed to subscribe for an additional SEK 1 million and Board member and CEO Ulf Bladin has committed to subscribe for an additional SEK 1 million.

In addition to the subscription commitment from Fredrik Alpsten and additional subscription commitments from Kiarash Farr and Ulf Bladin totaling SEK 5 million, Prolight has received additional subscription commitments and subscription intentions from existing shareholders of approximately SEK 2.1 million. In total, the Rights Issue is thus covered by subscription commitments and subscription intentions of approximately SEK 23.3 million, corresponding to 23.2 per cent of the Rights Issue.

Nominated Chairman of the Board, Fredrik Alpsten, comments:
During my years in the life sciences sector, I have witnessed the significant and rapidly growing need for point-of-care solutions. Prolight’s point-of-care system has an incredibly important role to play in contributing to fast and accurate diagnoses. The results obtained last week from fresh whole blood samples taken from cardiac patients at St Thomas’ Hospital were highly significant. They also confirmed Prolight’s previous positive preclinical validation study using biobank plasma samples. It is therefore only natural for me to be committed to the company not only as a board member, but also as a major shareholder.

Subscription commitments and subscription intentions
In addition to previously communicated subscription commitments, the Company can now announce that the Company's nominated Chairman of the Board Fredrik Alpsten has committed to subscribe for shares with and without preferential rights of SEK 3 million in the Rights Issue. Fredrik is nominated to be elected and take office at the Annual General Meeting to be held on June 30, 2025. In addition to Fredrik, the Company's CEO and Board member Ulf Bladin has also committed to subscribe for shares for an additional SEK 1 million, corresponding to a total commitment of SEK 2 million. In addition to Ulf and Fredrik, Board member Kiarash Farr has also committed to subscribe for shares for an additional SEK 1 million, corresponding to a total commitment of SEK 1.5 million.

In addition to the above and previously communicated commitments, the Company has received additional subscription commitments and subscription intentions from existing shareholders of approximately SEK 2.1 million. The Rights Issue is covered by subscription commitments of approximately SEK 21.7 million, corresponding to approximately 21.6 percent of the Rights Issue, and subscription intentions of approximately SEK 1.6 million, corresponding to approximately 1.6 percent of the Rights Issue. In total, the Rights Issue is thus covered by subscription commitments and subscription intentions of approximately SEK 23.3 million, corresponding to 23.2 percent of the Rights Issue.

No compensation will be paid for the submitted subscription commitments. The commitments are not secured pledged assets, restricted funds or similar arrangements. Subscription intentions are not a written commitment.
Indicative timetable

June 16 – June 25, 2025Trading in subscription rights (TR) on NGM
June 16 – June 30, 2025Subscription period in the Rights Issue
June 16 – July 16, 2025Expected trading in paid subscribed shares
(BTA) on NGM
July 2, 2025Estimated date for announcement of issue outcome

Advisors
Mangold Fondkommission AB is financial advisor and Advokatfirman Lindahl KB is legal advisor to the Company in connection with the Rights Issue.